Your browser version may not work well with NCBI's Web applications. More information here...
1: Expert Opin Biol Ther. 2005 Apr;5(4):601-6.Click here to read Links

CDP-870 (certolizumab) in rheumatoid arthritis.

Kaushik VV, Moots RJ.

University of Liverpool Academic Rheumatology Unit, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool, L97AL, UK.

The development of biological anti-TNF-alpha therapy has revolutionised the treatment of rheumatoid arthritis and other inflammatory diseases, and has identified a worldwide market for expensive yet effective therapies for chronic diseases. Certolizumab (CDP-870) is a new agent that employs a novel strategy to neutralise TNF-alpha--namely the prokaryotic expression of TNF-alpha-specific Fab antibody fragments, coupled to polyethylene glycol--to produce a drug that is potentially less expensive to manufacture than other anti-TNF-alpha agents and which may be administered by subcutaneous injection once a month. The background to the ongoing development of this new agent and its clinical effects are discussed in this article.

PMID: 15934837 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Docusate (Docusate calcium, Stool softener, Sulfolax, ...)

    How do the drugs used to treat chronic constipation and irritable bowel syndrome with predominant constipation compare?

  • Certolizumab Injection (Cimzia® )

    Certolizumab injection is used to relieve the symptoms of Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in people who can no lon...

  • Source: AHFS Consumer Medication Information